Kajian klinikal Melanoma di Oklahoma
14 kajian untuk Melanoma sedang mencari peserta di lokasi di Oklahoma.
Bandar di Oklahoma
Teks kajian rasmi (Bahasa Inggeris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06246916Pan-tumor MRD Study
- Oklahoma Cancer Specialists and Research Institute (OCSRI), Tulsa
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 3
Umur 75 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07068074A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT04511013Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Retina Consultants of Oklahoma, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07015190Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- OU Health Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT05549297SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774BostonGene and Exigent Genomic INsight Study
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2025 · NCT06272864Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Nov 2024 · NCT03860883Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.